A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a new study conducted by researchers at King's College London (KCL ...

Fasenra is approved for treating severe eosinophilic asthma. AZN is also evaluating Fasenra in late-stage studies for treating nasal polyps and COPD among others. Last month, the FDA approved ...

Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma, making $1.3 billion in sales last year. It is also being developed for other indications including ...

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is changing how certain asthma injections are administered.

the drug could also face strong competition from AstraZeneca’s AZN Fasenra, also an IL-5 inhibitor. This AZN drug is currently approved for two indications, namely eosinophilic asthma and EGPA.